Disclosure Content Sample Clauses

Disclosure Content. In a transparency disclosure, Pfizer may identify both the Institution and the Principal Investigator, but will clearly differentiate between payments or other transfers of value to institutions and those made to individuals. Disclosures may include identifying information for institutions and investigators, such as name, business address, specialty, National Provider Identifier (NPI), and licensure numbers.
Sample 1Sample 2
AutoNDA by SimpleDocs
Disclosure Content. Pfizer may identify Institution and Principal Investigator, and will differentiate clearly between payments or other transfers of value made to institutions and those made to individuals. Disclosures may include identifying information for institutions and investigators, such as name, business address, specialty, license numbers.
Sample 1Sample 2
Disclosure Content. On the initial Closing Date and each subsequent Closing Date, (i) the Prospectus shall not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) there shall not have been, since the respective dates as of which information is given in the Prospectus, any material adverse change in the condition (financial or otherwise), earnings, business affairs or assets of the Company or any Subsidiary, whether or not arising in the ordinary course of business, (iii) no action, suit or proceeding at law or in equity shall be pending or, to the Knowledge of the Company, threatened against the Company or any Subsidiary that would be required to be set forth in the Prospectus other than as set forth therein, and no proceedings shall be pending or, to the Knowledge of the Company, threatened against the Company or any Subsidiary before or by any federal, state or other commission, board or administrative agency wherein an unfavorable decision, ruling or finding could reasonably be expected to have a Material Adverse Effect, other than set forth in the Prospectus, (iv) the Company shall have complied, in all material respects, with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the initial Closing Date and each subsequent Closing Date, as applicable, (v) the other representations and warranties of the Company set forth in Section 5. of this Agreement shall be accurate in all respects as though expressly made at and as of the initial Closing Date and each subsequent Closing Date, as applicable, and (vi) no regulatory or judicial proceeding which could reasonably result in a suspension or curtailment of the Offering shall be pending or, to the Knowledge of the Company, threatened. On the initial Closing Date and each subsequent Closing Date, the Agent shall have received a certificate of the Company’s President and of the Chief Financial Officer to such effect.
Sample 1
Disclosure Content. Pfizer may identify Grant Recipient and Project Lead/Principal Investigator, and will differentiate clearly between payments or other transfers of value made to institutions and those made to individuals. Disclosures may include identifying information for institutions and investigators, such as name, business address, specialty, license numbers.
Sample 1

Related to Disclosure Content

  • Disclosure Controls and Procedures The Company maintains effective “disclosure controls and procedures” (as defined under Rule 13a-15(e) under the Exchange Act to the extent required by such rule).

  • Accounting Controls and Disclosure Controls The Company and each of its subsidiaries maintain effective internal control over financial reporting (as defined under Rule 13-a15 and 15d-15 under the 1934 Act Regulations) and a system of internal accounting controls sufficient to provide reasonable assurances that (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, since the end of the Company’s most recent audited fiscal year, there has been (1) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (2) no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company and each of its subsidiaries maintain an effective system of disclosure controls and procedures (as defined in Rule 13a-15 and Rule 15d-15 under the 1934 Act Regulations) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and is accumulated and communicated to the Company’s management, including its principal executive officer or officers and principal financial officer or officers, as appropriate, to allow timely decisions regarding disclosure.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!